The Latin American guideline for the treatment of chronic hepatitis B;Guía Latinoamericana de tratamiento de la hepatitis crónica B

Acta Gastroenterologica Latinoamericana

Volumn 37, Issue 3, 2007, Pages 168-177

  Daruich, Jorge ^a   Gadano, Adrián ^b   Fainboim, Hugo ^c   Pessoa, Mario ^d   Cheinquer, Hugo ^e  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^c HOSPITAL F J MUÑIZ   (Argentina)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548794719     PISSN: 03009033     EISSN: 03009033     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment,current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.
2. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005;25:472-489.
3. Gish RG and Gadano AC. Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat 2006;13:787-798.
4. Campos RH, Mbayed VA, Pineiro and Leone FG. Molecular epidemiology of hepatitis B virus in Latin America. J Clin Virol 2005;34(Suppl 2):S8-S13.
5. Devesa M and Pujol FH. Hepatitis B virus genetic diversity in Latin America. Virus Res 2007;127:177-184.
6. Fainboim H, Pezzano S, Bouzas B y col. Genotipos de HBV en Buenos Aires, Argentina; distribucion y posible significado en diferentes situaciones clinicas. (Abst). Acta Gastroenterol Latinoam 2006;36(Suppl 3):S1-S110.
7. Lok AS and McMahon BJ. Chronic Hepatitis B. Hepatology 2007;45:507-539.
8. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003;38:533-540.
9. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-323.
10. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695.
11. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-1532.
12. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1717.
13. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006;44:283-290.
14. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010.
15. Gish R, Chang TT, de Man R, et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg-positive chronic hepatitis B patients (Study ETV-022). Hepatology 2005;42(Suppl):267[Abs].
16. Chang TT, Chao YC, Kaymakoglu S, et al. Entecavir maintained virologic supresión through three years of treatment in antiviral-naïve HBeAg positive patients (ETV 022/901). Hepatology 2006;(suppl 1):229[Abs].
17. Colonno R, Rose R, Pokornowski K, et al. Assessment at three years shows high berrier to resistance is maintained in entecavir-trated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology 2006;(suppl 1):229[Abs].
18. Lai C-L, Leung N, Teo E-K, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-536.
19. Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003;37:756-763.
20. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-1217.
21. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg negative chronic hepatitis B. N Engl J Med 2005;352:2673-2681.
22. Hadziyannis S, Sevastianos V, Rapti I and Tassopoulos N. Sustained biochemical and virological remission alter discontinuation of 4 to 5 years of adefovir dipivoxil treatment in HBeAg negative chronic hepatitis B. Hepatology 2006; (suppl 1):231[Abs].
23. Lai C-L, Shouval D, Lok AS, et al. Entecavir for HBeAg negative chronic hepatitis B. A randomized comparison of entecavir to lamivudine for treatment of HBeAg-negative chronic hepatitis B in nucleoside-naive patients. N Engl J Med 2006;354:1011-1020.
24. Lai C-L, Gane E, Hsu C-W, et al. Two-year results from the Globe trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs lamivudine. Hepatology 2006;44(Suppl 1):222[Abs].
25. Di Bisceglie A, Lai CL, Gane E, et al. Telbivudine GLOBE Trial: maximal Early HBV Suppression is Predictive of Optimal Two-Year Efficacy in Nucleoside-Treated Hepatitis B Patients. Hepatology 2006;44(Suppl 1):230[Abs].
26. Lusida MI, Sakugawa H, Nagano-Fujii M, et al. Genotype and subtype analyses of hepatitis B virus (HBV) and possible co-infection of HBV and hepatitis C virus (HCV) or hepatitis D virus (HDV) in blood donors, patients with chronic liver disease and patients on hemodialysis in Surabaya, Indonesia. Microbiol Immunol 2003;47:969-975.
27. Canbakan B, Senturk H, Tabak F, et al. Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial. J Gastroenterol Hepatol 2006;21:657-663.
28. Wedemeyer H, Yurdaydin C, Dalekos G et al "72 week data of the hidit-1 trial: a multicenter randomised study comparing Peginterferon alfa -2a plus Adefovir vs Peginterferon alfa -2a plus placebo vs Adefovir in chronic delta hepatitis. J Hepatol 2007;46(Suppl 1):4[Abs].
29. Fabrizi F, Bunnapradist S, Martin P. HBV infection in patients with end-stage renal disease Semin Liver Dis 2004;24(Suppl 1):S63-S70.
30. Girndt M, Kohler H Hepatitis B virus infection in hemodialysis patients Semin Nephrol 2002;22:340-350.
31. Idilman R, Arat M, Soydan E et al Lamivudine prophylaxis for prevention of chemotherapy -induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies, J of Viral Hepat 2004;11:141-147.
32. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies Br J Haematol 2007;136: 699-712.
33. Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinacional randomized controlled trial. Gastroenterology 1998;114:988-995.
34. Jonas MM, Kelley DA, Mizerski J, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002.
35. D•antiga L, Aw M, Atkins M, et al. Combined lamivudine/interferon alfa treatment in "immunotolerant" children perinatally infected with hepatitis B: a pilot study. J Pediatrics 2005;148:228-233.
36. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-1926.
37. Benhamou Y. Treatment algorithm for chronic hepatitis B in HIV-infected patients. J Hepatol 2006;44(Suppl 1):S90-S94.
38. Schmutz G, Nelson M, Lutz T, et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy f hepatitis B in HIV-coinfection. AIDS 2006;20:1951-1954.
39. Mc Mahon M, Lek j, Brennan M, et al. The HBV drug Entecavir-Effects on HIV-1 replication and resistance N. Engl J. Med 2007;356:2614-2625.
40. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: Mechanisms, detection and interpretation. J Hepatol 2006;44:593-606.
41. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004;48:3498-3507.
42. Lampertico P, Marzano A, Levrero M, Santantonio T, Di Marco V, Brunetto M, et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. Hepatology 2006;44(Suppl 1):693[Abs].
43. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-297.